ENTOD Pharmaceuticals gets DCGI nod to carry out the phase 3 trials of 0.05% atropine eye drops

Low-dose atropine has emerged as an effective approach to slow the progression of myopia in children

USFDA accepts dupilumab for priority review in adults with prurigo nodularis

Dupixent would be the first and only medicine specifically indicated to treat prurigo nodularis in the U.S., if approved

FDA approves Roche’s Evrysdi for use in babies under two months with SMA

Evrysdi has proven efficacy in babies, children and adults with more than 5,000 patients treated to date

Tetra Bio-Pharma appoints CFO

Auld is a seasoned Financial Executive with over 30 years of relevant experience

Mezzion Pharma receives clear FDA path forward for the approval of Udenafil for single ventricle heart disease

Jubilant HollisterStier enters into agreement of $149.6 mn with US Govt to expand critical vaccine manufacturing capacity

This agreement is in addition to the $92 million filling line expansion announced in November 2021

NATCO launches first generic version of Nexavar Tablets in the US

The product will be launched by NATCO's commercial partner Viatris.

Thyrocare unveils new brand identity

New logo reflects Thyrocare’s transformation since 1996 to its current leading position at the cutting edge of Diagnostic services

Novavax initiates phase 3 trial of its COVID-19 omicron booster

Trial will assess safety and antibody responses of NVX-CoV2515 to the Omicron variant of COVID-19

Glenmark Pharma reports revenue growth of 5.6% YoY in Q4

Glenmark Pharmaceuticals announced its financial results for the fourth quarter ended March 31, 2022